Share Name Share Symbol Market Type Share ISIN Share Description
Amryt Pharma LSE:AMYT London Ordinary Share GB00BDD1LS57 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.25p -1.02% 24.25p 23.50p 25.00p 24.25p 24.25p 24.25p 2,972.00 07:49:42
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -1.0 -4.2 - 50.52

Amryt Pharma Share Discussion Threads

Showing 1201 to 1225 of 1225 messages
Chat Pages: 49  48  47  46  45  44  43  42  41  40  39  38  Older
DateSubjectAuthorDiscuss
27/4/2017
17:38
geoffsmithAmryt. Better to focus on our real chance of sharing a decent revenue stream than our remote chance of sharing a much bigger revenue stream.
rossannan
27/4/2017
15:29
If you are right geoffsmith that would make Novelion shares a buy!
papillon
27/4/2017
14:39
rossannan, Who`s we. There results are brilliant and very significant, they will be looked at in depth by the industry, I think ownership of Lojuxta will be desired by some in big pharma.
geoffsmith
27/4/2017
14:32
geoffsmithOne thing at a time, that is not what we are currently looking at.
rossannan
27/4/2017
14:21
rossannan, Yes of course the study treated suffers of HOFH, but it says "The study results confirmed that real world experiences of a cohort of Italian patients show that Lojuxta is a very powerful cholesterol-lowering agent." Please read that whole paragraph again, I don't think that this drug will only be available for suffers of HOFH. It could replace statins for patients who suffer the worse side effects of statins, and I think there are many of those.
geoffsmith
27/4/2017
13:58
geoffsmithThis is why "rare" is used repeatedly.
rossannan
27/4/2017
13:57
geoffsmithIs it not a bit more complex than that? It seems to be aimed at a specific condition, not just high cholesterol.
rossannan
27/4/2017
12:53
"It's a great shame AMYT don't own the IP to Lojuxta, we are adding value to someone else.". BUT also adding value to AMYT, tightfist. Have a look at the information concerning the Lojuxta licensing deal in the relevant AMYT RNS's. "Yes I see that amyrt just has an excusive license for the European economic area.". Not just that area, geoffsmith. I'm happy to continue to hold, AMYT and to maybe add on the dips. Unlike runwaypaul I'm NOT a "pumper & dumper" share ramper & deramper trader! Jacksonpollack is always complaining about the "BoD sitting on their backsides doing SFA for their wages", but then they are NOT a charity doing their work for the benefit of small shareholders! They are out to make money for themselves and hopefully, in the process, we will also make money. One thing is for certain the only TWO Executive Directors haven't been "sitting on their backsides doing SFA for their wages"!
papillon
27/4/2017
12:01
Hi Geoff Thanks for your reply. The problem with Lojuxta is it's cost. It is about 30k for 1 month's supply. If it does was the report says it can do, take up will improve and costs will come down. All the best. IB
icebreaker
27/4/2017
12:01
My comment yesterday about News Flow was well timed!It's a great shame AMYT don't own the IP to Lojuxta, we are adding value to someone else. Maybe it is a complementary commitment within the licence deal?.I am very curious that this work/potential hasn't already been executed in the U.S.? Or is the European or Italian setting radically different?Whatever, this cannot do the sales/margin of Lojuxta in Europe, MENA, Turkey any harm! And presumably we are now assured to hit the revenue targets with corresponding milestone payments.Cheers, tightfist
tightfist
27/4/2017
11:54
Hi Icebreaker, Yes I see that amyrt just has an excusive license for the European economic area. But say that big pharma want to own lojuxta, then surely they will want to buy that license back to take full control. If not either way this news surely indicates a potential very large uptake of the prescribing of Lojuxta.
geoffsmith
27/4/2017
11:53
Buffy: I looked at the RNS again. It does say "Ten of the 15 patients..."
bigwavedave
27/4/2017
11:51
Up 11% now which is more like it. I had double that in mind.
bigwavedave
27/4/2017
11:43
Hi Geoff If the big pharma do want Lojuxta they will surely go after Aegerion (subsidiary of Novelion) whose product it is? Good luck.
icebreaker
27/4/2017
11:27
curnic1, If Lojuxta does really do what this rns says then we don't need a flood of news anyway, I don't think the market has woken up yet to what this means. The big pharma companies will want this, am I dreaming or is this news real?
geoffsmith
27/4/2017
11:20
Massive News, Great News take your pick and this is just the start of a flood of Brilliant News in the near future.
curnic1
27/4/2017
11:11
Have I read this rns right I wonder, I have now read it all three times and cant really believe how good this appears, I know three men who have been on statins and found the side effects to be intolerable, so much so that they have stopped taking them,one of whom is now still suffering very unpleasant side effects some two years later. It reads to me that Lojuxta could and will replace statins for a hugh amount of people with bad cholesterol. Is this massive good news or what?
geoffsmith
27/4/2017
11:06
runwaypaul26 Apr '17 - 10:23 - 1074 of 1080 0 0 paps Hot Stock Rocket says STRONG HOLD. you know what you need to do.gl >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> In the light of today's RNS, runwaypaul, I should have bought yesterday!!!!!!!!!!!!!!!!! LOL. How many times do I have to tell you I do NOT base investment decisions on Hot Stock Rockets (which I DON'T subscribe to)/ShareProphets tips. You really are rather slow on the uptake runwaypaul! LOL. PS. The AMYT chart signals were saying sell AMYT yesterday, but a good(ish) RNS can blow a chart signal to smithereens!
papillon
27/4/2017
10:08
Well spotted buffy. Maybe the answer is in the full study. I only read the RNS with one eye open this morning but did expect a much higher move on this news which I think is excellent. Will read it properly later.
bigwavedave
27/4/2017
08:03
Hutch_PodMaybe not as simple as that - complex but on balance positive.
rossannan
27/4/2017
07:53
There were only 10 receiving aphoresis. It is those 10 he is referring too I think.
icebreaker
27/4/2017
07:18
15 patients 80% were able to stop the treatment The remaining 2 had their dose reduced Either the number of patients was 10 or the number of patients that didn't stop treatment was 3. What's happened to Mark Sumeray? Buffy
buffythebuffoon
27/4/2017
07:13
Buy the dips Sir!
ny boy
27/4/2017
07:12
Unexpected update today. Very positive I think.
hutch_pod
26/4/2017
10:23
paps Hot Stock Rocket says STRONG HOLD. you know what you need to do.gl
runwaypaul
Chat Pages: 49  48  47  46  45  44  43  42  41  40  39  38  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:35 V: D:20170428 08:27:12